Microsatellite instability and chemosensitivity in solid tumours

Sara Cherri, Ester Oneda, Silvia Noventa, Laura Melocchi and Alberto Zaniboni

Abstract: The use of biomarkers that influence a targeted choice in cancer treatments is the future of medical oncology. Within this scenario, in recent years, an important role has been played by knowledge of microsatellite instability (MSI), a molecular fingerprint that identifies defects in the mismatch repair system. This knowledge has changed clinical practice in the adjuvant setting of colon cancer, and its role in the neoadjuvant setting in gastric tumours is becoming increasingly interesting, as well as in endometrial cancers in both early and advanced diseases. Furthermore, it has undoubtedly conditioned the first lines of treatment in the metastatic setting in different types of cancers. The incidence of MSI is different in different cancer types, as well as in early cancers versus metastatic disease. Knowing the incidence of MSI in the various histologies can provide insight into the potential use of this biomarker considering its prognostic value, especially in the early stages, and its predictive role with respect to treatment response. In particular, MSI can guide the choice of chemotherapy treatments in the adjuvant setting of colon and perioperative setting in gastric tumours, which could lead to immunotherapy treatments in these patients in both the early stages of the disease and the metastatic setting where the response to immunotherapy drugs in diseases with MSI is now well established. In this review, we focus on colon, gastric and endometrial cancers, and we briefly discuss other cancer types where MSI could have a potential role in oncological treatment decisions.

Keywords: cancer, chemotherapy, colon cancer, endometrial cancer, gastric cancer, microsatellite instability

Received: 13 February 2022; revised manuscript accepted: 21 April 2022.

Introduction
Oncological clinical practice is increasingly aimed at identifying personalized and targeted drugs for the treatment of tumours. This has led to the search for targetable markers that identify patients who are more susceptible to a given treatment. This research primarily concerns biological drugs targeting certain molecular characteristics of the disease, unlike the use of chemotherapeutic drugs for which clinical research has not yet led to the identification of predictive response markers that would allow personalized treatments. However, in recent years, an aid to determining patient eligibility for standard chemotherapy treatments and identifying a proportion of unresponsive patients has been identified by increasing knowledge regarding the significance of microsatellite instability (MSI).¹ MSI is a molecular fingerprint that identifies defects in the mismatch repair system (dMMR). This mechanism involves a series of mismatch DNA repair enzymes, which are MutL homologue 1 (MLH1), MutL homologue 3 (MLH3), MutS homologue 2 (MSH2), MutS homologue 3 (MSH3), MutS homologue 6 (MSH6), postmeiotic segregation increased by 1 (PMS1) and postmeiotic segregation increased by 2 (PMS2). During normal DNA replication, the MSH2/MSH6 and MSH2/MSH3 heterodimeric complexes are responsible for detecting and binding DNA mismatch errors, while MLH1/PMS2 heterodimers are responsible for excision and resynthesis of the correct DNA bases in mismatch sites.
Therefore, loss of transcription or functional defects in one or more proteins of this fundamental control complex results in a systemic defect and consequent unsuccessful DNA repair. This favours the accumulation of mutations in brief repetitive DNA sequences called microsatellites, which are distributed throughout the coding and noncoding genome and are generally unstable and identical in all cells from an individual. They are particularly sensitive to DNA mismatch errors because the constant repeat of the same nucleotides causes slippage of the DNA polymerase and errors in the absence of an efficient correction system. MSI is the result of variation in the number of mononucleotide and dinucleotide repetitions in tumour cells compared with normal cells, and their difference in length can be used as a surrogate to indirectly identify a mismatch repair system deficiency (see Figure 1).

Standard diagnostic methods for identifying MSI in cancer include testing MSI status using molecular biology techniques or, in daily clinical practice, evaluating expression of the four MMR proteins by immunohistochemistry (IHC) on histological tissue sections as a valid surrogate to identify tumours with a higher probability of instability, though there is a slight and well-documented discordance between these two methods. IHC is a relatively simple and widely available technique in all pathology laboratories that enables identification of the specific defective MMR protein by comparing expression between tumour cells and adjacent normal tissue. On the contrary, IHC can be subject to preanalytical issues and fixation artefacts (false negatives), as well as aberrant or heterogeneous staining and false-positives because 6–7% of MSI tumours retain MMR IHC expression due to catalytically inactive mutated MMR proteins or other more complex molecular and epigenetic mechanisms underlying MSI, such as polymerase epsilon (POLE) mutations or MLH1 promoter methylation. In these cases, and generally when IHC results are indeterminate or open to interpretation, MSI molecular testing should be performed according to Bethesda and European Society for Medical Oncology (ESMO) guidelines. MSI testing is based on polymerase chain reaction (PCR) amplification of microsatellite markers using different panels available comprising a combination of mononucleotide and dinucleotide repeats. Thus, MMR-IHC and MSI-PCR exhibit high concordance (90–95%), but both tests should be performed to assess eligibility for treatment, as a recent report demonstrated that nearly 10% of patients enrolled for immunotherapy in metastatic colorectal cancer (CRC) had false-positive dMMR or MSI-PCR results. Next-generation sequencing (NGS) represents an appropriate alternative molecular test for assessing MSI and tumour mutational burden (TMB), especially in non-Lynch-associated tumours, where the molecular mechanisms driving MSI can be more complex and involve more genes and unusual pathways. Nevertheless, NGS can be performed only in selected centres due to the expensive and required expertise.

The hypotheses that have been formulated to explain the biological mechanisms underlying resistance to chemotherapy of MSI-associated diseases primarily concern adjuvant fluorouracil-based treatments in CRC. Often cited in the literature are studies on the antitumor immune response, represented by the lymphocyte infiltrate that characterizes MSI diseases and which would be the basis for the best prognosis of these patients, an advantage contrasted by the immunosuppressive effects of chemotherapy and that explains the lack of benefit of fluoropyrimidine (FP)-based chemotherapy. It is important to contextualize that these studies refer to stage II CRCs. According to some authors, the addition of irinotecan or oxaliplatin counteract resistance to fluorouracil in MSI tumours. However, these hypotheses have not been confirmed in randomized studies. Another interesting hypothesis is provided by an in vitro study in which it would seem that mismatch repair proteins are fundamental for establishing the fluorouracil (FU)–DNA complex and that their deficiency reduces the binding of FU to DNA and consequently the antitumor drug effect. Regardless of hypotheses on the potential chemoresistance of MSI diseases, it is clear that this molecular marker plays a fundamental role in clinical oncology practice.

In this review, we will refer to the state of MMR/deficiency or MSI/high using the term MSI to refer more generally to the fingerprint that characterizes these diseases.

Based on the patient’s history and familial information, genetic counselling is suggested for suspected Lynch syndrome. Young patient age, familial cases of Lynch syndrome-related cancers (colon cancer, gastric cancer, endometrial cancer) and absence of MMR proteins in cancer
tissue require genetic testing. NGS techniques allow multiple gene analyses and are useful for resolving doubts regarding hereditary or sporadic cancer origin, leading to tailored familial screening and surveillance.\textsuperscript{18}

Currently, in clinical practice, in Europe, determining the status of microsatellites is required only in patients diagnosed with colon and endometrial cancers\textsuperscript{19,20}, while in the United States it is also recommended in gastric cancer.
This review aims to provide an overview of the possible use of this molecular fingerprint with particular attention to the chemosensitivity of neoplasms with MSI and the possible implications of this information in the therapeutic decision-making process.

**Colorectal cancer**

CRC is one of the most common cancers in terms of incidence and mortality, ranking third as a cause of cancer-related death worldwide.21 Currently, two different molecular genetic pathways have been distinguished, one involving chromosomal instability (CIN) and the other involving MSI. With respect to CIN, there are a series of genetic changes leading to the activation of proto-oncogenes (e.g. K-RAS, CTNNB1 and PIK3CA) and inactivation of tumour suppressor genes (e.g. p53, APC, SMAD2/4). This genetic pathway represents the most frequent pathogenetic alteration of CRCs, occurring in up to 80% of cases.22 The second pathway of colorectal carcinogenesis is represented by MSI.

Greater awareness of the diversity of CRC and the implication that this difference has in the pharmacological management of these diseases has been conferred by the discovery of MSI. Currently, 10–25% of colon cancers are estimated to have MSI, of which 3% are hereditary and associated with Lynch syndrome, while the remaining 12% are caused by somatic and acquired hypermethylation of the MLH1 gene promoter. The prevalence of MSI in rectal cancer is less frequent than that in colon cancer, occurring in approximately 10% of cases.23 MSI CRCs have a phenotype including a greater onset in the right colon, a better prognosis and a decreased susceptibility to chemotherapy. They are also characterized by a lymphocytic infiltrate with a prominent inflammatory reaction that is poorly differentiated and often presents as the mucinous type.24 CRC oncogenesis is characterized by a sequential accumulation of genetic alterations that overcome the redundant control mechanisms built into each cell, resulting in gradual tumour development. Several studies have attempted to determine how these alterations develop in an attempt to differentiate and recognize different phenotypes of CRCs. Among these studies, data published by the international multicentre study led by Bert Vogelstein and Albert de la Chapelle elucidated the clinical implications of MSI, demonstrating that deletion mutations in microsatellite sequences were widespread in inherited CRCs and in 13% of sporadic cases, indicating that hereditary cancers and a subset of sporadic cancers share a unique path of tumour development.25 These observations have important implications for the clinical practice of CRC, both in localized disease and in the metastatic setting. In this context, rectal cancer will be discussed separately.

**Colon cancer**

Determining the status of microsatellites has certainly gained in popularity due to its predictive value in directing management with conventional chemotherapy or novel-targeted agents and its prognostic significance for patient.26 In recent years, the clinical management of CRC has seen important practice changes in both adjuvant and inoperable settings.

The primary clinical trials investigating the predictive role of MSI status on chemotherapy response are shown in both settings in Table 1, which summarizes the primary studies investigating the predictive role of MSI in colon cancer.

**Resectable tumours**

The first study published on the responsiveness of CRC with respect to MSI by Elsaleh *et al.*,27 concluded that cancers with MSI were more sensitive to adjuvant chemotherapy than tumours without MSI. This conclusion, which was subsequently demonstrated to be incorrect, derives from the design of this study; in particular, the assignment of patients to the treatment groups was at the discretion of oncologists rather than randomized. In fact, a careful evaluation of the study population shows that the patients selected for chemotherapy were characterized by fewer comorbidities and better performance status.

However, subsequent studies investigating the role of MSI as a predictor of response to chemotherapy treatments in the adjuvant setting did not show any benefit for chemotherapy in patients with MSI CRC (Table 1).

In particular, studies conducted by Ribic in 2003 and Sargent in 2010 provided evidence of the lack
Table 1. Predictive and prognostic role of MSI in colorectal cancer.

| Author/trial | Study type | No. of MSI/all patients | Year of publication | Stage of disease | Therapy regimen | Results in MSI tumours |
|--------------|------------|-------------------------|---------------------|------------------|----------------|-----------------------|
| Elsaleh et al. | Consecutive patients | 63/656 | 2000 | III | 5-FU-based cht | Benefit of adj cht |
| Ribic et al. | Randomized (specimens from five randomized trials) | 95/570 | 2003 | II–III | 5-FU-based cht | No benefit of adj cht |
| De Vos tot Nederveen Cappel et al. | Retrospective | 47/92 | 2004 | III | 5-FU-based cht | No benefit of adj cht |
| Storojeva et al. | Randomized (specimens from trial of SAKK) | 21/60 | 2005 | NS | 5-FU/mitomycin | No benefit of adj cht, no correlation with OS and DFS in untreated patients |
| Benatti et al. | Consecutive patients | 256/1263 | 2005 | I–IV | 5-FU-based cht | No benefit of adj cht, better prognosis in stage II and III |
| Popat et al. | Pooled analysis | 1277/7642 | 2005 | NS | 5-FU | No benefit of adj cht, better prognosis |
| Lanza et al. | Consecutive patients | 114/718 | 2006 | II–III | 5-FU | Better prognosis, especially among patients without adj cht |
| Jover et al. | Consecutive patients | 66/754 | 2006 | II–III | 5-FU | No benefit of adj cht |
| Kim et al. | Randomized | 98/542 | 2007 | II–III | 5-FU/LV | No benefit of adj cht, increased RFS but no difference in OS |
| Des Guetz et al. | Meta-analysis | 454/3690 | 2009 | II–III | 5-FU-based cht | No benefit of adj cht |
| Bertagnolli et al. | Randomized | 96/723 | 2009 | III | 5-FU/LV versus IFL | Better DFS in MSI patients treated with IFL, no if treated with 5-FU/LV |
| Sargent et al. | Consecutive patients | 70/457 165/1027 | 2010 | II–III | 5-FU-based cht | No benefit of adj cht |
| Klingbiel et al. | Pooled analysis | 190/1254 | 2015 | II–III | 5-FU/LV or FOLFIRI | Stage II: RFS and OS better regardless of cht arm (adding irinotecan no added benefit), Stage III: RFS slightly better but no difference in OS |
| André et al. | Randomized | 95/1008 | 2015 | II–III | 5-FU/LV versus FOLFOX | Better DFS and OS, trends in favour of FOLFOX |
| Tougeron et al. | Retrospective | 433/433 | 2016 | II–III | FP +/- oxaliplatin | Adding oxaliplatin improved DFS contrary to FP alone and only in stage III |
| Sinicrope et al. | Pooled analysis NCCTG N0147, NSABP C-08 | 73/832 | 2017 | | FOLFOX +/- bevacizumab or cetuximab | Better SAR, Worse SAR in mutant BRAFV600E |
| Author/trial | Study type | No. of MSI/all patients | Year of publication | Stage of disease | Therapy regimen | Results in MSI tumours |
|-------------|------------|-------------------------|---------------------|-----------------|-----------------|-----------------------|
| Zaanan et al. | Pooled analysis NCCTG N0147 and PETACC8 | 252/2501 | 2018 | III | FOLFOX | Favourable prognostic factor in a multivariate analysis |
| Chouhan et al. | Retrospective cohort study | 95/686 | 2018 | III | 5-FU-based cht | Neither BRAF nor MSI were individually predictive of OS benefit, benefit of adjuvant cht only if MSI + BRAFmut |
| Taieb et al. | Pooled analysis MOSAIC, NCCTG N0147, PETACC8, PETACC3, NSABP C07, NSABP C08, AVANT | 271/2630 | 2019 | Recurrence following adjuvant cht in stage III | 5-FU-based cht | Longer SAR regardless of BRAF status (shorter SAR in BRAFmut even if MSI) |
| Aggarwal et al. | Meta-analysis | 437/3051 | 2021 | NS | Adjuvant setting | 5-FU | MSI status does not alter 5-year OS of patients treated with adjuvant 5-FU |
| Cohen et al. | Pooled analysis 12 adjuvant trials | 609/5457 | 2021 | III | 5-FU/LV +/- oxaliplatin | Adding oxaliplatin to 5-FU improves OS and DFS. Better outcomes in the N1 group but similar OS in the N2 group |
| Müller et al. | Randomized | 4/108 | 2008 | IV | FP-oxaliplatin-based first-line adjuvant cht | Lower rate of response with cht, no correlation with OS and PFS |
| Overman et al. | Phase II | 74/74 | 2017 | IV | Nivolumab in subsequent lines | ORR 31%, DCR 69% 12-month OS 73% |
| Overman et al. | Phase II | 119/119 | 2018 | IV | Nivolumab + ipilimumab in subsequent lines | ORR 55%, DCR 80% 12-month PFS 71% 12-month OS 85% |
| Lenz et al. | Phase II | 45/45 | 2021 | IV | Nivolumab + low-dose ipilimumab, first line | ORR 69%, DCR 85% [13% CR] |
| André et al. | Randomized | 307/307 | 2020 | IV | Pembrolizumab versus 5-FU-based cht +/- bevacizumab or cetuximab | PFS 16.5 versus 8.2 months |

5-FU, 5-fluorouracil; Adj, adjuvant; Cht, chemotherapy; CR, complete response; DCR, disease control rate; DFS, disease-free survival; FOLFIRI, 5-fluorouracil/leucovorin + irinotecan; FOLFOX, 5-FU/LV + oxaliplatin; FP, fluoropirimidine; IFI, weekly bolus irinotecan + 5-FU/LV; LV, leucovorin; MSI, microsatellite instability; MSS, microsatellite stability; NS, not specified; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; SA, survival after recurrence; SAKK, Swiss Group for Clinical Cancer Research.
of survival benefit in stage II MSI CRC patients receiving adjuvant 5-FU.\textsuperscript{15,27}

Currently, it is known that the prevalence of the MSI phenotype in stage II CRC is approximately 10–15%, and it is usually associated with lower N stage and poor differentiation. These patients also have an excellent prognosis compared with those with microsatellite stability (90 versus 66%) and potential resistance to 5-fluorouracil.\textsuperscript{52}

For this reason, current international guidelines recommend that stage II patients with MSI tumours should not receive adjuvant treatment with 5-FU-based chemotherapy.\textsuperscript{18} However, this assumption is not always valid, although MSI status represents to date the most reliable molecular prognostic marker for deciding the management for stage II CRCs. In fact, this biomarker cannot be used without considering other prognostic factors. Specifically, in recent guidelines published by the ESMO for patients with nonmetastatic colon cancer, patients having fewer than 12 lymph nodes examined or T4 staging should be considered at high risk regardless of their microsatellite status. The role of MSI in this subgroup is currently considered uncertain.\textsuperscript{53}

In stage III patients, the role of MSI as a predictive biomarker of response to chemotherapy is not fully understood,\textsuperscript{37} although the MSI phenotype remains a favourable prognostic factor in patients with stage III colon cancer receiving adjuvant 5-FU-based chemotherapy.\textsuperscript{41}

Various studies have attempted to clarify these associations, but controversy still exists regarding the utility of several molecular markers for predicting survival in the context of adjuvant chemotherapy for stage III CRCs. For example, the study conducted by Chouhan \textit{et al.} concluded that the MSI test is predictive of the response to adjuvant chemotherapy in stage III colon cancer only when the results are interpreted in combination with BRAF. In particular, neither BRAF status nor MSI was individually predictive of survival benefit, but rather, the association between these two biomarkers was predictive.\textsuperscript{42} In fact, BRAF mutation configures a proportion of CRC tumours a poor prognosis, reducing the benefits derived from MSI. In a pooled analysis, survival after relapse in patients with stage III CRC treated with chemotherapy in the adjuvant setting was higher in the MSI phenotype than in the MSS phenotype. The BRAFV600E mutation was a poor prognostic factor in both MSI and MSS patients.\textsuperscript{42} Similar results emerged from a study led by Sinicrope \textit{et al.},\textsuperscript{41} underlining the importance of these biomarkers for patient management at recurrence.

To date, adjuvant chemotherapy with FP and oxaliplatin in patients with the stage III CRC MSI phenotype remains the gold standard. In a study conducted by Cohen \textit{et al.} of 5457 patients, the addition of oxaliplatin to 5-fluorouracil improved overall survival (OS) and disease-free survival (DFS) in patients with MSI stage III CC. The better prognosis of patients with MSI compared with MSS was confirmed in patients with N1 stage, while it was comparable in patients with N2 stage.\textsuperscript{45}

Given the high efficacy of immunotherapy drugs in patients with metastatic CRC MSI and the uncertain role of chemotherapy in stages II and III in this category of patients, the hypothesis of performing adjuvant treatment with immunotherapy has emerged in recent years. The patients with MSI CRC who hypothetically could benefit most are in the T4 or N2 stages, which is the proportion of patients with the highest risk of relapse. In addition to T and N factors, several future biomarkers could aid in the selection of patients, such as the presence of persistent circulating tumour DNA after surgery.\textsuperscript{54} Several clinical trials are currently validating the efficacy of immunotherapy, combined with chemotherapy or monotherapy, in these patient settings. Two phase III randomized trials for resected stage III MSI CRC are ongoing: the ATOMIC study, which is evaluating FOLFOX (5-FU/LV + oxaliplatin) ± atezolizumab for 6 months plus maintenance with atezolizumab or placebo for 6 months (NCT02912559), and the POLEM study (NCT03827044), which evaluates 24 weeks of FP versus 12 weeks of FP plus oxaliplatin ± avelumab for MSI or patients with POLE mutation.

\textbf{Metastatic setting}

The use of MSI in clinical practice for metastatic CRCs has become mandatory due to the implications of these data in selecting the best first-line therapy to offer to the patient.\textsuperscript{55} In fact, MSI has been configured as a strong predictor of efficacy in blocking the immune checkpoint, leading to the approval of immunotherapy drugs for MSI patients with metastatic CRC. This important
milestone has the most important added value to clinical practice in CRC tumours in recent years. The increased response to immunotherapy drugs of MSI patients is correlated with the high TMB and the burden of neoantigens, favouring the infiltration of immune effector cells and the anti-tumor immune responses within these tumours.\textsuperscript{56} The infiltration of specific subgroups of functional immune cells into these tumours is currently considered the cause of the good prognosis and low risk of relapse in surgically treated patients with stage I, II and III disease.\textsuperscript{57}

The US Food and Drug Administration (FDA) approval of pembrolizumab, an anti-PD1 monoclonal antibody, in patients with MSI metastatic tumours of any histology is due to the clinical study conducted by Le \textit{et al.}, who enrolled 32 patients comprising 11 and 21 CRC patients with MSI and MSS, respectively. Objective response at 20 weeks and PFS rates were 40\% and 78\%, respectively, in CRC patients with MSI tumours compared with 0\% and 11\% for those with MSS tumours.\textsuperscript{58} These results were confirmed in a subsequent study by Andrè \textit{et al.},\textsuperscript{49} as reported in Table 1.

Another anti-PD-1 monoclonal antibody, nivolumab, was studied in monotherapy or in combination with ipilimumab (anti-CTLA-4 monoclonal antibody) in a phase II study in MSI CRC patients. The results of this study suggest a superior efficiency of combination therapy of nivolumab + ipilimumab compared with monotherapy with nivolumab (PFS at 12 months 71\% versus 50\%; OS 85\% versus 73\%).\textsuperscript{49}

Although these data are very encouraging, the proportion of patients who have access to these new drugs is limited considering that the majority of patients present with MSS cancers for which immune checkpoint blockade fails to achieve better survival. This necessitates greater molecular knowledge of these diseases and the search for additional biomarkers of susceptibility to anti-PD1 antibodies. Ongoing research on MSS tumours with DNA POLE mutations, comprising 2–3\% of CRCs, is very interesting. In fact, these enzymes are involved in the mechanisms of DNA repair, and tumours with POLE mutations are characterized by strong immune cell infiltration similar to MSI tumours and similarly respond to immunotherapy drugs.\textsuperscript{59} Therefore, despite the important therapeutic breakthroughs in CRC tumours, there is still much to understand. For example, overcoming the mechanisms of primary and secondary resistance to immunotherapy drugs in MSI patients represents an important challenge for CRC MSI disease.\textsuperscript{60,61}

\textbf{Rectal cancer}

Although colon cancer (CC) and rectal cancer (RC) are often referred to as a single entity (CRC), these two tumours are different in many regards. In fact, colon and rectal cancers differ from the perspective of molecular carcinogenic alterations, molecular profiles and enzymatic expression models.\textsuperscript{62} In particular, MSI is more frequently detected in proximal CC than in RC.\textsuperscript{63} As illustrated above, MSI CC tends to have a phenotype associated with proximal location and poor differentiation compared with MSS CC, a phenotype not observed in RC MSI.\textsuperscript{64} These two tumours also differ with respect to the therapeutic approach, which is characterized by multiple modifications. However, most studies do not differentiate these two neoplasms but refer to CC and RC tumours as a single entity, especially in the metastatic setting. A separate argument can be made on locally advanced RC disease.

To date, the biological markers identifying patients with locally advanced RC who would benefit from neoadjuvant chemotherapy treatment are unknown. Several studies have investigated the utility of MSI data in selecting patients for induction chemotherapy by studying its correlation with different outcomes, such as complete pathological response (pCR), downstaging, posttreatment stage or regression grade. pCR is currently considered the most important prognostic factor. A study by Hasan \textit{et al.} enrolled a total of 5086 patients with locally advanced RC recorded in the American College of Surgeons National Cancer Database. This retrospective analysis found that MSI is independently associated with a reduction in pCR for locally advanced RC after neoadjuvant chemoradiation.\textsuperscript{65} However, these data on the reduced response to induction chemotherapy of MSI patients compared with MSS patients are not consistent across all published studies. Specifically, some studies have hypothesized an association between MSI and increased pCR rates,\textsuperscript{66,67} while other studies found no association between MSI and the pCR rate.\textsuperscript{68,69} A meta-analysis of the published literature revealed no significant differences between MSI and MSS patients treated with induction chemotherapy for locally advanced RC.\textsuperscript{70}
However, today, it is common practice to use total neoadjuvant therapy consisting of neoadjuvant chemotherapy followed by chemoradiotherapy. Based on these data, the role of MSI status remains to be clarified and to date cannot be used as a selection factor or a predictor of response to neoadjuvant chemotherapy/chemoradiotherapy. Furthermore, neoadjuvant strategies using immunotherapy and chemoradiotherapy are being evaluated in clinical trials, and they could advance understanding regarding the most appropriate therapeutic management of these patients.

Gastric cancer

Gastric cancer (GC) is one of the world’s leading causes of cancer morbidity and mortality, ranking fifth in incidence and third in mortality.71 The 5-year survival rate remains very low because most patients are diagnosed with metastatic disease. Chemotherapy drugs used in the metastatic setting have slightly improved the life expectancy of these patients. A potential improvement in the survival of these patients could be achieved by more precise medicine. A potential improvement for a more targeted treatment could be provided by a more specific classification that considers the molecular characteristics of the disease.

The classification used since 1965 is the Lauren classification, in which gastric adenocarcinoma is basically divided into two distinct types, the intestinal subtype, which is the most common, and the diffuse subtype, involving a third of patients and having a worse prognosis.72

Recently, a classification based on the molecular profile was defined by The Cancer Genome Atlas (TCGA), identifying four distinct gastric cancer subtypes: Epstein–Barr virus (EBV)-positive, microsatellite unstable tumours (MSI), genomically stable tumours (GS), and chromosomal tumour instability (CIN).73 This molecular classification does not currently impact clinical practice; however, it helps to identify a number of patients potentially susceptible to immunotherapeutic treatments. In particular, EBV-positive and MSI tumours are associated with signatures suggesting potential responsiveness to immunotherapy treatments.74 Data published in a meta-analysis that included 34 studies reported a prevalence of MSI in 10.7% of intestinal type versus 2.9% and 0.9% for diffuse and mixed type, respectively.75 For sporadic and hereditary tumours, there do not seem to be significant differences in the frequency of the MSI signature;76 instead, it appears to be linked to tumour staging.

In fact, the percentage of patients with MSI appears to be related to the stage of the disease, occurring more often in patients with low N0 stage (approximately 20%) and significantly less frequently in metastatic disease (<5%).71 The incidence of MSI in nonmetastatic GC tumours makes the potential use of this biomarker very intriguing, particularly in the neoadjuvant and adjuvant settings, with the aim of improving the results obtained from neoadjuvant treatment, where chemotherapy still provides too low of a benefit in terms of pCR and DFS (see Table 2).

Perioperative/adjuvant chemotherapy

The first choice for therapy in patients with GC with operable T2 or higher or N+ includes perioperative chemotherapy treatment.98 In patients fit for polychemotherapy, the standard of care is represented by the FLOT scheme (fluorouracil plus leucovorin, oxaliplatin and docetaxel), which has shown a benefit in terms of OS superior to previously used chemotherapy regimens, such as EOF (epirubicin, oxaliplatin, fluorouracil) and ECX (epirubicin, cisplatin, xeloda).99 This indication is currently independent of the molecular profile of the disease, including MSI. However, in the current literature, several findings indicate that MSI has relevance in therapeutic decision-making in this disease setting.

These observations were suggested by subpopulation data from two major studies. In particular, in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) study, where non-Asian patients with GC were enrolled as candidates for perioperative chemotherapy, patients with the MSI molecular profile exhibited worse survival outcomes in the chemotherapy plus surgery arm [hazard ratio (HR), 2.22; 95% confidence interval (CI), 1.02–4.85; p = 0.04].88 Similar results emerged from the CLASSIC study in the adjuvant setting in patients with surgical GC, where once again patients with MSI seem to experience no advantage from chemotherapy, in this case in terms of 5-year DFS (DFS for chemotherapy versus surgery-only groups: 83.9% versus 85.7%; p = 0.93).87

A meta-analysis conducted by Pietrantonio et al.,89 which included the aforementioned MAGIC and CLASSIC trials and an additional
## Table 2. Predictive and prognostic role of MSI in gastric cancer.

| Author/trial | Study type | Stage of disease | Therapy regimen | Results in MSI tumours |
|--------------|------------|------------------|-----------------|------------------------|
| An et al. | Retrospective | Radically resected | 5-FU-based cht | No benefit in DFS in stage I-II with adj cht, no significant prognostic value |
| Kim et al. | Retrospective | Radically resected stage II–III | Adj cht or surgery alone | Good prognosis with surgery alone, benefits attenuated by cht |
| Marrelli et al. | Retrospective | Radically resected | I–IV | Positive prognostic value but limited to non-cardinal intestinal type cancer. No significant difference in DFS for MSI patients compared to MSS |
| Sohn et al. | Retrospective (data from a TCGA cohort) | I–IV | – | Poorer OS than those with EBV subtype but better than those with GS subtype |
| Polom et al. | Meta-analysis | Resectable | Preoperative cht platinum-based | Positive prognostic value (HR for OS MSI versus MSS: 0.69) |
| Hashimoto et al. | Retrospective | Resectable | Preoperative cht | Negative predictive value for response to neoadj cht. If no neoadj cht RFS longer in MSI patients, if neoadj cht no significant difference in RFS |
| Haag et al. | Retrospective | Resectable | Neoadj cht | Positive prognostic value of MSI in DFS and OS |
| Di Bartolomeo et al. | Randomized (Translational Analysis from the ITACA-S Trial) | Radically resected stage II–III | 5-FU/LV versus sequential FOLFIRI and cisplatin-docetaxel | Independent positive prognostic factor (better DFS and OS) |
| Kim et al. | Retrospective | 2 cohorts: I–III | FP-based cht | Better DFS and OS for patients treated with surgery alone |
| Kim et al. | Retrospective | Radically resected stage II–III | 5-FU CRT versus surgery alone | No benefit of adj CRT |
| Choi et al. | CLASSIC Randomized (post hoc analysis) | Radically resected stage I–III | CAPOX versus observation | No benefit of adj cht |
| Smyth et al. | MAGIC Randomized (post hoc analysis) | Radically resected stage I–III | Perioperative ECF versus surgery alone | No benefit of adj cht |
| Pietrantonio et al. | Meta-analysis | Radically resected | Depending on the trial: perioperative ECF, perioperative 5-FU, FOLFIRI and cisplatin-docetaxel, cisplatin + capecitabine, CRT | MSI is a robust prognostic marker: 5-year DFS 71.8% versus 52.3%, 5-year OS 77.5% versus 59.3% |

(Continued)
| Author/trial                  | Study type | MSI GC/all patients (no.) | Stage of disease | Therapy regimen | Results in MSI tumours                                                                 |
|------------------------------|------------|---------------------------|------------------|----------------|--------------------------------------------------------------------------------------|
| Kohlruss et al.              | Retrospective | Before neoadj cht 15/143; in resected tumours 59/617 | Resectable       | Platinum/5-FU-based neoadj cht         | MSI and EBV are not predictive of response to neoadj cht (better response in MSS), but indicative of a good prognosis, in particular MSI irrespective of treatment with cht. |
| Fuchs et al. KEYNOTE-059    | Phase II   | 7/259                     | IV, advanced line | Pembrolizumab   | ORR 57.1%                                                                            |
| Marabelle et al. KEYNOTE-158 | Phase II   | 24/233                    | IV, advanced line | Pembrolizumab   | ORR 45.8%, PFS 11 months                                                               |
| Janjigian et al. CHECKMATE-032 | Phase I–II | 11/160                    | IV, advanced line | Nivolumab or nivolumab plus ipilimumab | ORR 44.4%, DCR 77.8%                                                                   |
| Pietrantonio et al.          | Meta-analysis | 123/2545                  | IV: first line, maintenance or second line according to the trial | Anti PD1/PD-L1 therapy, according to the trial | HR for OS 0.34 (versus 0.85 in MSS) HR for PFS 0.57                                    |
| Andre et al. GARNET          | Phase I    | 8/106                     | IV, advanced line | Dostarlimab     | ORR 37.5                                                                             |
| Janjigian et al. CHECKMATE-649 | Phase III  | 44/1581                   | IV, first line   | Nivolumab + cht versus cht alone (cht: XELOX or FOLFOX) | HR for OS 0.33 (versus 0.73 MSS)                                                      |
| Chao et al. POST hoc analysis of: KEYNOTE-059 | Post hoc analysis of: KEYNOTE-059 | 7/174                     | IV: third line or higher | Pembrolizumab   | OS and PFS NR ORR 57.1%                                                              |
| KEYNOTE-061                  |            | 27/514                    | Second line      | Pembrolizumab versus paclitaxel        | PFS 17.8 months (versus 3.5 months) ORR 46.7% (versus 16.7%)                        |
| KEYNOTE-062                  |            | 50/682                    | First line       | Pembrolizumab +/− cisplatin and 5-FU/capecitabine versus cht alone | PFS 11.2 months (versus NR versus 6.6 months) ORR 57.1% (versus 64.7% versus 36.8%) |

5-FU, 5-fluorouracil; Adj, adjuvant; CAPOX, capecitabine + oxaliplatin; Cht, chemotherapy; CRT, chemoradiotherapy; DCR, disease control rate; DFS, disease-free survival; EBV, Epstein–Barr virus; ECF, epirubicin + cisplatin + fluorouracil; FOLFIRI, 5-fluorouracil/leucovorin + irinotecan; FOLFOX, 5-FU/LV + oxaliplatin; FP, fluoropirimidines; GC, gastric cancer; GS, genomically stable; HR, hazard ratio; LV, leucovorin; MSI, microsatellite instability; MSS, microsatellite stability; Neoadj cht, neoadjuvant chemotherapy; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; TCGA, The Cancer Genome Atlas.
two trials (ARTIST and ITACA-S), confirmed the favourable prognosis of patients with MSI GC compared with MSS patients, confirming the lack of survival benefit from perioperative chemotherapy. These data are currently changing the clinical practice of MSI-operable GC patients.

Conversely, data on the benefit of adjuvant chemotherapy treatment in patients with MSI GC after surgery are discordant. Some data, in line with stage II colon cancers, seem to confirm a lack of benefit or even a detrimental effect of chemotherapy in this setting, while other data exhibit the opposite trend with a benefit to adjuvant chemotherapy treatments in MSI patients with gastric cancer. At present, MSI data cannot be used in the therapeutic decision-making process in the adjuvant setting.

**Metastatic treatment**

As previously reported, published data suggest that patients with an MSI signature or EBV could benefit from the use of immunotherapy drugs. The first data to demonstrate the efficacy of immunotherapy drugs, in this case pembrolizumab, was the KEYNOTE-012 study. In particular, patients with PD-L1+ advanced GC presented a response to treatment in 22% of cases. Of these patients, a substantial percentage (17%) had MSI. Furthermore, among MSI patients, the response to treatment was surprising, reaching 50% of patients. In a second phase II study involving a cohort of patients with gastric/gastroesophageal junction cancer treated with pembrolizumab, patients with MSI status experienced an objective response rate (ORR) of 57.1%, markedly distinguishing themselves from patients with MSS, who had a lower ORR (9%).

Data on the efficacy of immunotherapy drugs in advanced gastric MSI patients were extrapolated from the results of the Garnet study, which evaluated the efficacy of dostarlimab in patients with pretreated MSI solid tumours. The study was originally designed for patients with MSI advanced endometrial cancers; however, study cohort F also enrolled patients with other tumour histologies, particularly gastrointestinal tract cancers (93% of the total). The confirmed ORR in MSI patients was 38.7% (95% CI: 29.4–48.6), with a complete response rate of 7.5%, demonstrating a remarkable response to treatment in this pretreated patient setting.

A meta-analysis conducted by Pietrantonio et al. enrolled a consistent number of patients, for a total of 2545 patients, of whom 4.8% had MSI status. From this meta-analysis, it emerged that MSI GC patients treated with pembrolizumab experienced a benefit in terms of higher OS than MSS patients (HR for OS of 0.34 versus 0.82).

In fact, the literature significantly confirms the utility of information on MSI in patients with GC, both in the perioperative and metastatic settings, to identify the most effective treatment for this group of patients.

**Endometrial cancer**

Endometrial cancer (EC) is the most common gynaecologic malignancy in the United States. In most cases (approximately 67%), it presents in the early stage with an 81% 5-year OS rate, while survival decreases in the advanced stage to only 17–15%. Among modifiable risk factors associated with the development of endometrial cancer, the strongest correlation is observed with obesity and metabolic syndrome, while approximately 2–5% of endometrial cancers have a germline mutation of the mismatch repair genes that leads to Lynch syndrome.

Historically, EC was classified into two histopathologic categories: types 1 and 2. Type 1 cancers are the most frequent, being low-grade oestrogen-driven endometrioid tumours, while type 2 cancers are high-grade nonendometrioid tumours. Recently, this classification has been refined, thanks to TCGA, with a genomic classification that proposes four groups: POLE ultramutated, MSI hypermutated (MSI-H), copy-number low and copy-number high, which represent prognostic predictors of response to therapy.

Approximately 30% of localized and 13–30% of recurrent ECs are MSIs. In this review, we focused on the prognostic role of MSI status on the response to chemotherapy and the possible benefit of immunotherapy. Indeed, a dramatic response to immune checkpoint inhibitors (ICIs) was observed in MSI EC. However, the prognostic value of TMB, PD-L1 expression, tumour-infiltrating lymphocytes (TILs) and Janus kinase 1 (JAK1) and β2-microglobulin (B2M) mutations in MSI EC patients needs to be clarified.

Table 3 reports the primary studies on MSI EC.
| Author/Firm | Study Type | No. MSI/EC/all patients | Year of publication | Stage of disease/setting | Therapy regimen | Results in MSI tumours |
|------------|------------|------------------------|---------------------|------------------------|-----------------|------------------------|
| Resnick et al. | Retrospective | 15/477 | 2010 | Adjuvant | RT or Cht | No difference in OS and PFS in OS and PFS if nonendometrioid tumours treated with RT |
| Kim et al. | Retrospective | 16/352 | 2016 | Adjuvant | RT and Cht | Lower rate of recurrence & no difference in OS if OS in a multivariable analysis |
| Loukovaara et al. | Retrospective multicentre cohort study | 28/795 | 2020 | Adjuvant | RT | No effect on disease-specific survival |
| Leon-Castillo et al. | Phase III | 137/410 | 2019 | IBII, grade 3, endometrioid, adjuvant | RT | Adj RT improved survival |
| Reijnen et al. | Retrospective | 49/233 | 2020 | IV, advanced line | Pembrolizumab | ORR 57.1%, PFS 27.5%, OS NR |
| Marabelle et al. | Retrospective | 49/233 | 2020 | IV, advanced line | Pembrolizumab | ORR 63.6% versus 36.2% in MSI, DCR 91% versus 89% months versus 7.4 in MSI, OS NR |
| Oaknin et al. | Phase II | 13/42 | 2020 | IV, advanced line | Pembrolizumab | ORR 42.3% versus 12.7%, CRI, DOR NR |
| Mekker et al. | Phase III | 16/33 | 2019 | IV, advanced line | Pembrolizumab | ORR 26.7%, MSS cohort closed because of futility |
| Antill et al. | Phase II | 36/71 | 2019 | IV, advanced line | Pembrolizumab | ORR 42.7%, PFS 8.3 months versus 1.8 in MSI, 12-month OS 71% versus 51% in MSI, OS NR |

| Year of publication | Stage of disease/setting | Therapy regimen | Results in MSI tumours |
|---------------------|------------------------|-----------------|------------------------|
| 2010 | Adjuvant | RT or Cht | No difference in OS and PFS in OS and PFS if nonendometrioid tumours treated with RT |
| 2016 | Adjuvant | RT and Cht | Lower rate of recurrence & no difference in OS if OS in a multivariable analysis |
| 2020 | Adjuvant | RT and Cht | No effect on disease-specific survival |
| 2019 | IBII, grade 3, endometrioid, adjuvant | RT | Adj RT improved survival |
| 2020 | IV, advanced line | Pembrolizumab | ORR 57.1%, PFS 27.5%, OS NR |
| 2020 | IV, advanced line | Pembrolizumab | ORR 63.6% versus 36.2% in MSI, DCR 91% versus 89% months versus 7.4 in MSI, OS NR |
| 2020 | IV, advanced line | Pembrolizumab | ORR 42.3% versus 12.7%, CRI, DOR NR |
| 2019 | IV, advanced line | Pembrolizumab | ORR 26.7%, MSS cohort closed because of futility |
| 2019 | IV, advanced line | Pembrolizumab | ORR 42.7%, PFS 8.3 months versus 1.8 in MSI, 12-month OS 71% versus 51% in MSI, OS NR |
Resectable tumours

Treatment for early-stage disease has historically been total hysterectomy and bilateral salpingo-oophorectomy with or without adjuvant radiotherapy. Adjuvant chemotherapy is indicated based on risk factors for relapse [histological subtype such as nonendometrioid type, grade 3 histology, myometrial invasion $\geq 50\%$, lymphovascular space invasion (LVSI), lymph node metastases and tumour diameter $\geq 2\ cm$]. Maggi et al. found no difference in PFS or OS comparing five cycles of cisplatin, doxorubicin and cyclophosphamide to external pelvic radiation in high-risk patients. Furthermore, a Japanese multicentre randomized trial reached the same conclusion, with no difference in OS, relapse rate or PFS between whole-pelvic irradiation with three or more courses of cyclophosphamide, doxorubicin and cisplatin chemotherapy in patients with high-risk EC. However, in the NSGO/EORTC trial, a statistically significant improvement in PFS and cancer-specific survival was observed for combined chemoradiotherapy (CTRT) compared with radiotherapy alone.

In these studies, doxorubicin/platinum-based regimens were used for four to six cycles, and the regimen most commonly used was paclitaxel plus carboplatin (TC). Radiotherapy (RT) is variably used before or after chemotherapy or in a ‘sandwich’ modality, with three cycles of chemotherapy administered before and after radiotherapy. However, when chemotherapy was given after pelvic radiotherapy, there was a higher rate of cytopenia that required granulocyte-colony stimulating factor use during chemotherapy. Recently, the PORTEC-3 trial investigated the role of pelvic radiotherapy versus whole pelvic radiotherapy with two concomitant doses of cisplatin followed by four courses of CP in high-risk women. The trial reported a benefit of 5% for 5-year OS and 7% for 5-year failure-free survival (FFS) with CTRT, with a greater benefit observed in serous cancer subgroups. A subsequent analysis investigated the prognostic relevance of molecular classification in the benefit of adjuvant treatment. Out of 410 EC samples analysed, 22.7% exhibited abnormal expression of p53 (p53abn), 12.4% had an exonuclease domain of DNA Polymerase Epsilon (POLE) mutation (POLEmut), 33.4% had a protein loss MMR (MSI) and 31.5% displayed no specific molecular profile (NSMP). The strongest negative prognostic factor was p53abn, and this subgroup had a worse prognosis but benefitted the most from CTRT treatment (22.4% benefit in relapse-free survival and 23.1% advantage in OS). Furthermore, 71% of serous tumours were found to have a p53 mutation, and their prognosis was equal to that of the nonserous subtypes that had the mutation. This suggests that p53 status allows the identification of a larger and more selected subgroup of patients who may benefit from adjuvant treatment with CTRT. Ultramutated EC with POLEmut subgroups results in a proofreading dysfunction during DNA replication that elicits a cytolytic immune response and impairs the function of cancer cells by decreasing their metastatic potential. POLEmut ECs are associated with a good prognosis with any treatment, suggesting that the prognosis is independent of adjuvant therapy. MSI ECs also have a deficit in DNA damage repair with an accumulation of mismatches, insertions and deletions that elicit a strong immune response that gives this subgroup of ECs an intermediate prognosis. The MSI and NSMP subgroups did not benefit from CTRT versus RT alone in the PORTEC-3 trial. Thus, RT remains an effective, well-tolerated and appropriate adjuvant treatment in high-risk early-stage MSI EC.

The best adjuvant strategy is under investigation in the PORTEC-4 trial (NCT03469674), which stratifies patients into three prognostic profiles (favourable, intermediate and unfavourable) based on the four TCGA molecular subtypes and integrates them with other prognostic factors, such as substantial invasion of the lymphovascular space, expression of L1-cell adhesion molecules and expression of CTNNB1. Women with high-risk EC are randomized to vaginal brachytherapy or adjuvant treatment (no treatment for a favourable profile, brachytherapy for an intermediate profile and pelvic RT for an unfavourable profile). More selectively, the TransPORTEC clinical trial plans seek to refine adjuvant treatment based on the Molecular Profile Program (RAINBO). Stage II/III MMRd EC patients are randomized to RT versus RT plus an ICI (Green-MMRd trial). The ADELE trial aims to evaluate the efficacy of ICI tislelizumab plus chemotherapy in the adjuvant setting after chemoradiation in high-risk MMRd EC.

Metastatic setting

In advanced or recurrent EC, hormonal therapy or chemotherapy can be used. Progestin agents are indicated for low-grade tumours with...
endometrioid histology, while TC is the standard first-line chemotherapy with a median PFS of 13 months and a median OS of 37 months.\textsuperscript{130}

In the first line, the comparison between TC and the paclitaxel-doxorubicin-cisplatin (TAP) regimen showed noninferiority of TC with a more manageable toxicity profile than TAP.\textsuperscript{131} The MITO END-2 study evaluated the addition of bevacizumab to first-line TC or recurrent EC but failed to demonstrate an increase in PFS.\textsuperscript{130} However, the study did report an increased ORR at 6 and 12 months.\textsuperscript{130} A limitation of this study is the absence of an assessment of predictive biomarkers for the response to bevacizumab in the four EC subtypes. Indeed, p53-mutated patients have been recently observed to exhibit improved PFS and OS when treated with TC plus bevacizumab \textit{versus} temsirolimus.\textsuperscript{132}

Unfortunately, no randomized study has currently performed a subgroup analysis considering the four TCGA molecular groups. ICI monotherapy demonstrated antitumour activity in MSI EC pretreated with an ORR of 42.3\% for dostarlimab, 26.7\% for avelumab, 40\% for durvalumab, 38\% for nivolumab and 57\% for pembrolizumab.\textsuperscript{92,117,119–121} Unfortunately, the mechanisms of primary resistance to immunotherapy are unknown, and predictive indicators of ICI response are not available. To stimulate a greater response, several phase III trials are investigating the role of ICI combination therapy in first-line MSI EC: dostarlimab (RUBY; NCT03981796), atezolizumab (AtTEnd; NCT03603184) and pembrolizumab (GY018', NCT02549209) in combination with TC chemotherapy against TC, lenvatinib with pembrolizumab \textit{versus} TC (NCT03572478)\textsuperscript{105} and durvalumab plus olaparib \textit{plus} TC \textit{versus} durvalumab plus TC \textit{versus} placebo plus TC (NCT04269200).

Pembrolizumab plus lenvatinib has shown efficacy in advanced EC that progresses after previous treatment.\textsuperscript{133} The final primary efficacy analysis reports an ORR of 38\% at 24 weeks, 63.6\% (30.8–89.1\%) in patients with MSI tumours (n = 11) and 36.2\% (26.5–46.7\%) in patients with MSS tumours (n = 94). Regardless of MSI status, the median duration of response was 21.2 months, the median PFS was 7.4 months and the median OS was 16.7 months. Several combination therapies are being studied in previously treated EC patients: nivolumab plus ipilimumab (NCT02982486), nivolumab plus indoleamine 2,3-dioxygenase inhibitor (BMS986205; NCT04106414), lenvatinib plus pembrolizumab plus doxorubicin or weekly paclitaxel (NCT03517449), rucaparib plus nivolumab (NCT03572478)\textsuperscript{107} and IMGN853 plus pembrolizumab (NCT03835819).

**MSI prognostic value across other cancer types**

MSI status has assumed increasing importance as a prognostic and predictive factor, in some cases modifying clinical practice, including in colorectal, gastric and endometrial adenocarcinomas. The clinical guidelines currently recommend the MSI testing be performed only for colorectal and endometrial cancers, but it is understandable that, given its importance in therapeutic decision-making in these pathologies, an increasing interest in research has arisen over the years about the prevalence and extent of MSI among other cancers.

In this chapter, we describe the primary studies in the literature investigating the incidence and possible therapeutic implications of MSI status in different tumour types.

With respect to incidence, a study published by Bonneville \textit{et al.}\textsuperscript{131} investigated these data in different tumour histotypes, leading to a very interesting general picture. The authors extrapolated data on the full exomes of 11,139 tumour-normal pairs from TCGA and Therapeutically Applicable Research for a total of 39 cancers. From these data, it emerged that MSI status was present in 27 of the 39 cancer histotypes evaluated, for an overall positivity of 3.8\%. The important incidence of MSI detected in cancers such as adrenocortical carcinoma (ACC, 4.3\%), cervical cancer (2.6\%) and mesothelioma (2.4\%) is very interesting, suggesting a potential role of MSI data in these cancer types. In particular, it could pave the way for new therapeutic options, given the known sensitivity of MSI tumours to ICIs and therefore to the broadening of the indication for the MSI test.

A recent review suggests that ACC could be associated with Lynch syndrome.\textsuperscript{134} Indeed, the prevalence of Lynch syndrome in ACC is 3.2\%, which is higher than that in the general population.\textsuperscript{135} However, when treatment with ICIs has been investigated in ACC patients, the efficacy is scarce.\textsuperscript{136,137} The majority of patients were heavily pretreated, and the number of MSI patients was very low. Pembrolizumab resulted in an ORR of
Concerning cervical cancer, there are few data in the literature; in particular, the prognostic role of MSI in these patients is not clear. In a cohort of patients with HPV + cervical cancer ($n=95$), 12% of MSI patients were identified. In some studies that included women with HPV + cervical cancer treated with immunotherapy, there were no promising results; however, MSI data for patient selection were not used in these studies. In a phase II study that evaluated the efficacy and safety of nivolumab in patients with advanced or recurrent uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma (STS), a potential predictive role of MSI in response to nivolumab was hypothesized. These data remain to be confirmed; to date, there is no clinical study that has selected these patients based on MSI data.

Regarding mesothelioma, despite the data published by Bonneville et al. where the incidence of MSI in mesothelioma seems significant, there are very few data in the literature. In a large retrospective study, data were collected from 335 patients with malignant pleural mesothelioma. The study did not identify any patients with malignant pleural mesothelioma with MSI, for which it concluded that the response to anti-programmed cell death 1-based immunotherapy may be driven by other mechanisms. Another study conducted in Spain reached similar conclusions.

Following the evolution of the use of the MSI signature in CC, much interest has aroused a possible similar use in other pathologies of significant oncological impact for incidence, such as breast cancer. Unfortunately, the percentage of MSI breast cancers is very low. Currently, the indication for immunotherapy for breast tumours concerns only the triple-negative phenotype, and PD-L1 positivity is used as a predictor of response. In a study that included MSI triple-negative breast cancer patients, MLH1 protein expression was inversely correlated with PD-L1 expression. Therefore, the study concluded that MMR protein testing may warrant further study, as these proteins could provide information to predict which patients might benefit from ICIs. Consistently, from data published in the literature, the loss of MMR proteins in breast tumours appears to be a more common event than MSI and exhibits intratumour heterogeneity. In particular, in a study that included breast cancer patients with both hormone-positive (HR+) and oestrogen-receptor-negative (HR−) phenotypes, patients with HR− breast cancers treated with chemotherapy lived longer in cases of MMR-deficient ($n=9$) than MMR-proficient ($n=33$) or MMR-heterogeneous ($n=7$) tumours.

Concerning prostate cancer (PC), the prevalence of MSI is approximately 3%, and approximately 20% of patients present with Lynch syndrome. However, data regarding the incidence of MSI come only from studies using immunotherapy, while the possible prognostic role of MSI in chemotherapy- and hormonal therapy-naive patients has not been investigated. Undoubtedly, some features of prostatic tumours, such as aggressive histology, ductal type, homologous recombination deficiency (HRD) mutations, high TMB and MSI, can affect subgroups of patients potentially sensitive to ICIs. Of the 32 MSI PC patients from the Memorial Sloan Kettering Cancer Center database, 11 were treated with ICIs, 6 (54.4%) exhibited a half decline in prostate-specific antigen levels, and 4 had a pathological response. In particular, pembrolizumab showed some efficacy in small studies with advanced MSI PC with an ORR of 60%. Other studies have tested ICIs alone or in combination with endocrine therapy in an unselected PC population with an ORR less than 20%. Considering the limited data on PC immunotherapy, we must await the results of ongoing studies with several combination approaches that will hopefully clarify the subgroup of patients who most benefit from ICIs.

Regarding cholangiocarcinoma, MSI has been reported in 5–10% of cases. The eight MSI biliary tract cancers (BTCs) included in the basket trial with pembrolizumab achieved an ORR of 25% with two complete responses and four stable diseases. Similarly, the 22 MSI BTCs in Keynote 158 displayed an ORR of 40.9% with 2
complete responses and 7 partial responses, an mPFS of 4.2 months and an mOS of 24.3 months.92 Unfortunately, all other immunotherapy studies in BTC included a population with no stratification for MMR genes and did not report significant benefits from ICI treatment.154 Less than 2% of pancreatic cancers exhibit MSI.155 The majority of them arise from the head and are associated with medullary and mucinous/colloid histology.156 Keynote 158 included 22 patients with MSI pancreatic cancer, one who achieved a complete response and three who achieved a partial response with an ORR of 18.2%, mPFS of 2.1 months and mOS of 4 months.93 Although the frequency of MSI in pancreatic cancer is very limited, in these patients where the therapeutic lines are scarce and the prognosis is poor, immunotherapy can represent a valid therapeutic option.

New studies with ICIs in the previous line or in combination therapy are needed to draw conclusions on their efficacy in MSI BTC patients.

Together, these findings highlight the need to more deeply understand the potential role of dMMR and MSI in cancer types.

**Discussion**

Microsatellites are regions of 10–60 base pairs that contain repetitions of 1–5 base pair motifs. The repetition of these loci along the genome is verified and maintained during cell division by the MMR system, which is involved in cellular DNA repair mechanisms. The compromise of this system, known as MMRd, can lead to microsatellite instability, called MSI. There are several mechanisms by which MMRd can occur, including both somatic and hereditary mutation of the germinal MMR pathway. MSI has aroused increasing interest, as it has been studied and well described in colorectal and gastric adenocarcinoma and in endometrial tumours, while little is known regarding the implications of this signature in other tumour types. The ramifications of these findings are both prognostic and predictive of response to cancer treatments.

Regarding the prognostic implications, the first known data on the prognosis of MSI tumours concern early colon cancer. In addition to the favourable prognostic data, these tumours are characterized by resistance to chemotherapy and do not benefit from adjuvant chemotherapy treatment with FPs.15 These data of good prognosis and chemoresistance therefore seem to be mutually inclusive in stage II CRCs, with the exceptions mentioned above. This convergence, however, is lost in stage III colon cancer, where the good prognosis of MSI tumours is maintained compared with MSS but not the reduced chemosensitivity; in fact, adjuvant chemotherapy according to the CAPOX (capecitabine plus oxaliplatin) or FOLFOX (5-fluorouracil plus oxaliplatin) scheme remains the therapeutic standard for this stage to date. It is also important to emphasize that MSI at this stage alone cannot guide prognostic evaluation, and other factors must also be considered. For example, BRAF mutation seems to predict a worse prognosis in patients with MSI stage III CRC.157,158 Concerning rectal cancer, which also exhibits a lower incidence of MSI tumours than CC, the role of this prognostic and predictive signature is less clear.159 To date, MSI data cannot be used when deciding up the choice of neoadjuvant chemoradiotherapy treatment compared with surgery alone in the potentially resectable setting.

Furthermore, data regarding the prognostic and predictive value of response to chemotherapy of MSI status in metastatic CC are discordant;160,161 however, a significant impact on patient survival in this setting has been achieved with the introduction of first-line immunotherapy in MSI patients.50,162

For gastric adenocarcinoma, the role of the MSI status has been widely recognized in recent years, leading to a new classification of GC that, compared with the well-known Lauren classification, in use since 1965, recognizes a subtype of MSI GC with well-defined characteristics and an expected response to immunotherapy treatments.72 The MSI phenotype has a higher incidence in the early stages than after metastasis72 and defines – within the potentially operable stages (I-III) – a subgroup of patients with better prognosis than the MSS counterpart in which there does not seem to be a benefit of neoadjuvant chemotherapy treatment compared with surgery alone, treatment that could be detrimental.89 To date, there are no randomized clinical trials, but data in the literature, albeit derived from retrospective studies and meta-analyses, are modifying current clinical practice in this category of patients, where in recent years, perioperative chemotherapy has been the gold standard in clinical practice. For the metastatic setting, in Europe,
the use of immunotherapy in advanced gastric tumours is not yet clinical practice outside clinical trials, while the FDA has approved the use of pembrolizumab in patients with MSI in this setting. Another monoclonal anti-PD1 antibody, dostarlimab, has obtained approval for patients with MSI solid tumours who have progressed on or following prior treatment and who have no satisfactory alternative treatment options, adding another step towards precision medicine.95

A very fitting example of the importance of the molecular characterization of the disease for the best therapeutic choice with the addition or elimination of chemotherapy, with its related toxicities, is given by the paradigm of adjuvant treatment in endometrial tumours, which in recent years has seen an ever greater refinement in the decision-making process. The choice of adjuvant treatment in these tumours is based on the evaluation of the presence of clinicopathological risk factors that allow the identification of low-, intermediate-, intermediate- and high-risk diseases with a range of therapeutic possibilities ranging from surgery alone to brachytherapy, pelvic radiotherapy and radiochemotherapy. In recent years, it has been understood that it is essential to add molecular information to this clinicopathological characterization, as molecular subgroups, including MSI tumours, have a greater prognostic impact than the histopathological characteristics of the tumours taken individually. In fact, the POLE mutated category seems to have a good prognosis regardless of the adjuvant chemotherapy treatment that could therefore be spared in this category of patients, and the MSI patients do not seem to benefit from the addition of chemotherapy to radiotherapy, while instead the p53 mutation recognizes a category of high-risk patients who benefit from adjuvant chemotherapy treatment in terms of recurrence-free survival.163

These data lead to the rationale on which ongoing trials are based, designing new therapeutic possibilities such as the use of checkpoint inhibitors in patients with POLE mut or MSI. Currently, molecular classification is not used in the metastatic setting, nor is it used by ongoing clinical trials in patient selection. However, this information is useful, as clinical trials evaluating the activity of pembrolizumab (KEYNOTE-158) and dostarlimab (GARNET) have shown high response rates in patients with MSI tumours.164 The data published in the literature on the discrepancy of MSI on relapsed disease compared with primary operated disease are interesting, suggesting the usefulness of rebiopsia on relapsed disease to redefine the molecular profile.165

We can therefore conclude that at present, MSI is used in the setting of localized disease for prognostic purposes and with the aim of refining adjuvant and neoadjuvant therapies in colon, gastric and endometrial cancers, as well as a marker predictive of response to treatment with checkpoint inhibitors in the metastatic setting. Unfortunately, not all ongoing clinical trials concerning these cancer types include MSI data among the characteristics of the study patients. However, considering what has been said thus far and the literature, this information could be invalidating, regarding not only immunotherapy trials but also chemotherapy trials, considering the potential chemoresistance or even detrimental role of chemotherapy in some categories of patients due to toxicity linked to avoidable treatment. For that reason, the collection of information from clinical trials could provide a key to understanding what is still not completely clear regarding the presence of MSI and the response to cancer treatments, whether they are chemotherapy or immunotherapy.

Finally, the acquisition of this information has led to a growing interest in the potential use of this molecular marker in other cancer histotypes where the incidence of MSI status could be higher than expected.

**Conclusion**

MSI has acquired increasing importance in recent years, so microsatellites have been included in new molecular classifications of diseases affecting colon, gastric and endometrial cancers. These classifications will lead to increasingly personalized cancer treatment. Achieving this goal cannot be exempt from the collection of information on the conditioning of the mutational status of microsatellites in the various disease settings and in the various tumour histologies, valuable information that will hopefully be provided by ongoing clinical research.

**Author contribution(s)**

Sara Cherri: Conceptualization; Writing – original draft.

Ester Oneda: Writing – original draft.
Silvia Noventa: Data curation.
Laura Melocchi: Supervision; Validation.
Alberto Zaniboni: Conceptualization; Supervision; Validation.

ORCID iD
Sara Cherri  https://orcid.org/0000-0001-7062-8723

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References
1. Li K, Luo H, Huang L, et al. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 2020; 20: 16.
2. Gilson P, Merlin JL and Harlé A. Detection of microsatellite instability: state of the art and future applications in circulating tumour DNA (ctDNA). Cancers 2021; 13: 1491.
3. Baretti M and Le DT. DNA mismatch repair in cancer. Pharmacol Ther 2018; 189: 45–62.
4. van Lier MG, Wagner A, van Leerdam ME, et al. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med 2010; 14: 181–197.
5. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008; 10: 293–300.
6. Malapelle U, Parente P, Pepe F, et al. Evaluation of microsatellite instability and mismatch repair status in different solid tumors: a multicenter analysis in a real world setting. Cells 2021; 10: 1878.
7. Hisson B, Crowe EP, Yantiss RK, et al. Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing. Mod Pathol 2018; 31: 1756–1766.
8. Sarode VR and Robinson L. Screening for Lynch syndrome by immunohistochemistry of mismatch repair proteins: significance of indeterminate result and correlation with mutational studies. Arch Pathol Lab Med 2019; 143: 1225–1233.
9. Hechtman JF, Rana S, Midhha S, et al. Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Mod Pathol 2020; 33: 871–879.
10. Nowak JA, Yurgelun MB, Bruce JL, et al. Detection of mismatch repair deficiency and microsatellite instability in colorectal adenocarcinoma by targeted next-generation sequencing. J Mol Diagn 2017; 19: 84–91.
11. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261–268.
12. Luchini C, Bibeau F, Litgenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumor mutational burden: a systematic review-based approach. Ann Oncol 2019; 30: 1232–1243.
13. Cohen R, Hain E, Buhard O, et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol 2019; 5: 551–555.
14. Phillips SM, Banerjea A, Feakins R, et al. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004; 91: 469–475.
15. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia Group B protocol 89803. J Clin Oncol 2009; 27: 1814–1821.
16. Zaanan A, Cuilliere-Dartigues P, Parc Y, et al. Impact of microsatellite instability and p53 expression on stage III colon cancer disease-free survival in patients treated by fluorouracil and leucovorin with or without oxaliplatin. J Clin Oncol 2008; 26(Suppl. 15): 15017.
17. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117: 123–131.
18. Malapelle U, Parente P, Pepe F, et al. Impact of pre-analytical factors on MSI test accuracy in mucinous colorectal adenocarcinoma: a multi-assay concordance study. *Cells* 2020; 9: 2019.

19. Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2021; 19: 329–359.

20. Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. *J Clin Oncol* 2015; 33: 209–217.

21. Mange S, Bellcross C, Cragun D, et al. Creation of a network to promote universal screening for Lynch syndrome: the LynchSyndrome Screening Network. *J Genet Couns* 2015; 24: 421–427.

22. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. *Lancet* 2019; 394: 1467–1480.

23. Cohen R, Buhard O, Cervera P, et al. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. *Eur J Cancer* 2017; 86: 266–274.

24. Nojadeh JN, Behrouz Sharif S and Sakhinia E. Microsatellite instability in colorectal cancer. *EXCLI J* 2018; 17: 159–168.

25. Kim ST, Lee SJ, Lee J, et al. The impact of microsatellite instability status and sidedness of the primary tumor on the effect of cetuximab-containing chemotherapy in patients with metastatic colorectal cancer. *J Cancer* 2017; 8: 2809–2815.

26. Boland CR and Goel A. Microsatellite instability in colorectal cancer. *Gastroenterology* 2010; 138: 2073–2087.

27. Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. *Lancet* 2000; 355: 1745–1750.

28. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N Engl J Med* 2003; 349: 247–257.

29. De Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. *Int J Cancer* 2004; 109: 468–471.

30. Storojeva I, Boulay JL, Heinimann K, et al. Prognostic and predictive relevance of microsatellite instability in colorectal cancer. *Oncol Rep* 2005; 14: 241–249.

31. Benatti P, Gafà R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis. *Clin Cancer Res* 2005; 11: 8332–8340.

32. Popat S, Hubner R and Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. *J Clin Oncol* 2005; 23: 609–618.

33. Lanza G, Gafà R, Santini A, et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. *J Clin Oncol* 2006; 24: 2359–2367.

34. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. *Gut* 2006; 55: 848–855.

35. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. *J Clin Oncol* 2007; 25: 767–772.

36. Des Guetz G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. *Eur J Cancer* 2009; 45: 1890–1896.

37. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J Clin Oncol* 2010; 28: 3219–3226.

38. Klingbiel D, Saridaki Z, Roth AD, et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. *Ann Oncol* 2015; 26: 126–132.

39. André T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. *J Clin Oncol* 2015; 33: 4176–4187.

40. Tougeron D, Mouillet G, Trouilloud I, et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study. *J Natl Cancer Inst* 2016; 108: djv438.
41. Sinicrope FA, Shi Q, Allegra CJ, et al. Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers: a secondary analysis of 2 randomized clinical trials. JAMA Oncol 2017; 3: 472–480.

42. Zaanan A, Shi Q, Taieb J, et al. Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: a pooled analysis from 2 randomized clinical trials. JAMA Oncol 2018; 4: 379–383.

43. Chouhan H, Sammour T, Thomas ML, et al. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU-based chemotherapy in stage III colon cancer. J Surg Oncol 2018; 118: 1311–1317.

44. Taieb J, Shi Q, Pederson L, et al. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol 2019; 30: 1466–1471.

45. Aggarwal N, Quaglia A, McPhail MJW, et al. Systematic review and meta-analysis of tumour microsatellite-instability status as a predictor of response to fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Colorectal Dis 2022; 37: 35–46.

46. Cohen R, Taieb J, Fiskum J, et al. Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. J Clin Oncol 2021; 39: 642–651.

47. Müller CI, Schulmann K, Reinacher-Schick A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 2008; 23: 1033–1039.

48. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18: 1182–1191.

49. Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/ microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018; 36: 773–779.

50. Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol 2022; 40: 161–170.

51. André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383: 2207–2218.

52. Dienstmann R, Mason MJ, Sinicrope FA, et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol 2017; 28: 1023–1031.

53. Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 1291–1305.

54. Cohen R, Shi Q and André T. Immunotherapy for early stage colorectal cancer: a glance into the future. Cancers 2020; 12: 1990.

55. Kishore C and Bhadra P. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Eur J Pharmacol 2021; 893: 173819.

56. Picard E, Verschoor CP, Ma GW, et al. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol 2020; 11: 369.

57. Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944–5951.

58. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509–2520.

59. Wang C, Gong J, Tu TY, et al. Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. J Gastrointest Oncol 2018; 9: 404–415.

60. Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov 2017; 7: 188–201.

61. Gurjao C, Liu D, Hofree M, et al. Intrinsic resistance to immune checkpoint blockade in a mismatch repair-deficient colorectal cancer. Cancer Immunol Res 2019; 7: 1230–1236.

62. Paschke S, Jafarov S, Staib L, et al. Are colon and rectal cancer two different tumor entities? A...
63. Reimers MS, Zeestraten EC, Kuppen PJ, et al. Biomarkers in precision therapy in colorectal cancer. *Gastroenterol Rep* 2013; 1: 166–183.

64. Hong SP, Min BS, Kim TI, et al. The differential impact of microsatellite instability as a marker of prognosis and tumor response between colon cancer and rectal cancer. *Eur J Cancer* 2012; 48: 1235–1243.

65. Hasan S, Renz P, Wegner RE, et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a National Cancer Database (NCDB) analysis. *Ann Surg* 2020; 271: 716–723.

66. Charara M, Edmonston TB, Burkholder S, et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. *Anticancer Res* 2004; 24: 3161–3167.

67. Lino-Silva LS, Gamboa-Domínguez A, Zúñiga-Tamayo D, et al. Mismatch repair protein expression and intratumoral budding in rectal cancer are associated with an increased pathological complete response to preoperative chemoradiotherapy: a case-control study. *World J Clin Oncol* 2018; 9: 133–139.

68. Du C, Zhao J, Xue W, et al. Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy. *Histopathology* 2013; 62: 723–730.

69. Huh JW, Kim HC, Kim SH, et al. Mismatch repair gene expression as a predictor of tumor responses in patients with rectal cancer treated with preoperative chemoradiation. *Medicine* 2016; 95: e2582.

70. O’Connell E, Reynolds IS, McNamara DA, et al. Microsatellite instability and response to neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. *Surg Oncol* 2020; 34: 57–62.

71. Rawla P and Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. *Prev Gastroenterol* 2019; 14: 26–38.

72. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965; 64: 31–49.

73. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; 513: 202–209.

74. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nat Med* 2018; 24: 1449–1458.

75. Polom K, Marano L, Marrelli D, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. *Br J Surg* 2018; 105: 159–167.

76. Leite M, Corso G, Sousa S, et al. MSI phenotype and MMR alterations in familial and sporadic gastric cancer. *Int J Cancer* 2011; 128: 1606–1613.

77. An JY, Kim H, Cheong JH, et al. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. *Int J Cancer* 2012; 131: 505–511.

78. Kim SY, Choi YY, An JY, et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analyses. *Int J Cancer* 2015; 137: 819–825.

79. Marrelli D, Polom K, Pascale V, et al. Strong prognostic value of microsatellite instability in intestinal type non-cardiac gastric cancer. *Ann Surg Oncol* 2016; 23: 943–950.

80. Sohn BH, Hwang JE, Jang HJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas Project. *Clin Cancer Res* 2017; 23: 4441–4449.

81. Hashimoto T, Kurokawa Y, Takahashi T, et al. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. *Gastric Cancer* 2019; 22: 785–792.

82. Haag GM, Czink E, Ahadova A, et al. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. *Int J Cancer* 2019; 144: 1697–1703.

83. Di Bartolomeo M, Morano F, Raimondi A, et al. Prognostic and predictive value of microsatellite instability, inflammatory reaction and PD-L1 in gastric cancer patients treated with either adjuvant 5-FU/LV or sequential FOLFIRI followed by cisplatin and docetaxel: a translational analysis from the ITACA-S trial. *Oncologist* 2020; 25: e460–e468.

84. Kim JW, Cho SY, Chae J, et al. Adjuvant chemotherapy in microsatellite instability-
high gastric cancer. Cancer Res Treat 2020; 52: 1178–1187.

85. Kim SM, An JY, Byeon SJ, et al. Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. Eur J Surg Oncol 2020; 46: 189–194.

86. An JY, Choi YY, Lee J, et al. A multi-cohort study of the prognostic significance of microsatellite instability or mismatch repair status after recurrence of resectable gastric cancer. Cancer Res Treat 2020; 52: 1153–1161.

87. Choi YY, Kim H, Shin SJ, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg 2019; 270: 309–316.

88. Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol 2017; 3: 1197–1203.

89. Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 2019; 37: 3392–3400.

90. Kohlruss M, Grosser B, Krenauer M, et al. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability. J Pathol Clin Res 2019; 5: 227–239.

91. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial [Erratum in: JAMA Oncol 2019; 5: 579]. JAMA Oncol 2018; 4: e180013.

92. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1–10.

93. Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer [Erratum in: J Clin Oncol 2019; 37: 443]. J Clin Oncol 2018; 36: 2836–2844.

94. Pietrantonio F, Randon G, Di Bartolomeo M, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open 2021; 6: 100036.

95. Andre T, Bertot D, Curigliano G, et al. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. J Clin Oncol 2021; 39(Suppl. 3): 9.

96. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27–40.

97. Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 2021; 7: 895–902.

98. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20.

99. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948–1957.

100. Tsai CY, Lin TA, Huang SC, et al. Is adjuvant chemotherapy necessary for patients with deficient mismatch repair gastric cancer? Autophagy inhibition matches the mismatched. Oncologist 2020; 25: e1021–e1030.

101. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016; 17: 717–726.

102. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.

103. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.

104. Meyer LA, Broaddus RR and Lu KH. Endometrial cancer and Lynch syndrome:
clinical and pathologic considerations. Cancer Control 2009; 16: 14–22.

105. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10–17.

106. Prendergast EN, Holman LL, LiuAY, et al. Comprehensive genomic profiling of recurrent endometrial cancer: implications for selection of systemic therapy. Gynecol Oncol 2019; 154: 461–466.

107. Green AK, Feinberg J and Makker V. A Review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book 2020; 40: 1–7.

108. Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase ε-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015; 1: 1319–1323.

109. Eggink FA, Van Gool IC, Leary A, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology 2016; 6: e1264565.

110. Gulhan DC, Garcia E, Lee EK, et al. Genomic determinants of de novo resistance to immune checkpoint blockade in mismatch repair-deficient endometrial cancer. JCO Precis Oncol 2020; 4: 492–497.

111. Cao W, Ma X, Fischer JV, et al. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomark Res 2021; 9: e002255.

112. Resnick KE, Frankel WL, Morrison CD, et al.Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. Gynecol Oncol 2010; 117: 234–238.

113. Kim SR, Pina A, Albert A, et al. Does MMR status in endometrial cancer influence response to adjuvant therapy? Gynecol Oncol 2018; 151: 76–81.

114. Loukovaara M, Pasanen A and Bützow R. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer. Cancer Med 2021; 10: 1034–1042.

115. León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020; 38: 3388–3397.

116. Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol 2019; 154: 124–130.

117. Oaknin A, Tinker AV, Gilbert LE, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020; 6: 1766–1772.

118. Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020; 38: 2981–2992.

119. Azad NS, Gray RJ, Overman MJ, et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol 2020; 38: 214–222.

120. Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019; 37: 2786–2794.

121. Antill Y, Yok PS, Robledo K, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer 2021; 9: e002255.

122. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105: 103–104.

123. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006; 95: 266–271.

124. Susumu N, Sega S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226–233.

125. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer – results from two randomised studies. Eur J Cancer 2010; 46: 2422–2431.

126. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced
endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. *Gynecol Oncol* 2009; 112: 543–552.

127. de Boer SM, Powell ME, Mileskih L, *et al.* Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. *Lancet Oncol* 2019; 20: 1273–1285.

128. Randall ME, Filiaci V, McMeekin DS, *et al.* Phase III ME: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. *J Clin Oncol* 2019; 37: 1810–1818.

129. Jamieson A, Bosse T and McAlpine JN. The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. *Ther Adv Med Oncol* 2021; 13: 17588359211035959.

130. Lorusso D, Ferrandina G, Colombo N, *et al.* Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 – a randomized phase II trial. *Gynecol Oncol* 2019; 155: 406–412.

131. Bonnerville R, Kook MA, Kauuto EA, *et al.* Landscape of microsatellite instability across 39 cancer types. *JCO Precis Oncol* 2017; 2017: PO.17.00073.

132. Leslie KK, Filiaci VL, Mallen AR, *et al.* Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: an NRG Oncology study. *Gynecol Oncol* 2021; 161: 113–121.

133. Makker V, Rasco D, Vogelzang NJ, *et al.* Lenalintib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol* 2019; 20: 711–718.

134. Georganztoglou N, Kokkali S, Tsourouflis G, *et al.* Tumor microenvironment in adrenocortical carcinoma: barrier to immunotherapy success? *Cancers* 2021; 13: 1798.

135. Raymond VM, Everett JN, Furtado LV, *et al.* Adrenocortical carcinoma is a lynch syndrome-associated cancer. *J Clin Oncol* 2013; 31: 3012–3018.

136. Carneiro BA, Konda B, Costa RB, *et al.* Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial. *J Clin Endocrinol Metab* 2019; 104: 6193–6200.

137. Le Tourneau C, Hoimes C, Zarwan C, *et al.* Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. *J Immunother Cancer* 2018; 6: 111.

138. Raj N, Zheng Y, Kelly V, *et al.* PD-1 Blockade in advanced adrenocortical carcinoma. *J Clin Oncol* 2020; 38: 71–80.

139. Wong YF, Cheung TH, Poon KY, *et al.* The role of microsatellite instability in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. *Gynecol Oncol* 2003; 89: 434–439.

140. Chung TK, Cheung TH, Wang VW, *et al.* Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinicopathological association. *Gynecol Obstet Invest* 2001; 52: 98–103.

141. Baay MF, Nakonieczny M, Woźniak I, *et al.* Microsatellite instability and HPV genotype in Polish women with cervical cancer. *Eur J Gynaecol Oncol* 2009; 30: 162–166.

142. Lheureux S, Butler MO, Clarke B, *et al.* Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma. *JAMA Oncol* 2018; 4: e173776.

143. Tamura K, Hasegawa K, Katsumata N, *et al.* Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. *Cancer Sci* 2019; 110: 2894–2904.

144. Arulananda S, Thapa B, Walkiewicz M, *et al.* Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. *J Thorac Oncol* 2018; 13: 1588–1594.

145. Cedrés S, Ponce-Aix S, Iranzo P, *et al.* Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. *Clin Transl Oncol* 2020; 22: 1390–1398.

146. Schmid P, Adams S, Rugo HS, *et al.* Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med* 2018; 379: 2108–2118.

147. Fusco N, Lopez G, Corti C, *et al.* Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability. *JNCI Cancer Spectr* 2018; 2: pky056.
148. Horimoto Y, Thinzar Hlaing M, Saeki H, et al. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. *Cancer Sci* 2020; 11: 2647–2654.

149. Abida W, Cytra J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer. *Proc Natl Acad Sci USA* 2019; 116: 11428–11436.

150. Rizzo A, Mollica V, Cimadamore A, et al. Is there a role for immunotherapy in prostate cancer? *Cells* 2020; 9: 2051.

151. Barata P, Agarwal N, Nussenzeig R, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. *J Immunother Cancer* 2020; 8: e001065.

152. Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. *Chin Clin Oncol* 2016; 5: 62.

153. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017; 357: 409–413.

154. Zayac A and Almhanna K. Hepatobiliary cancers and immunotherapy: where are we now and where are we heading? *Transl Gastroenterol Hepatol* 2020; 5: 8.

155. Taieb J and Abdallah R. How I treat pancreatic cancer. *ESMO Open* 2020; 4(Suppl. 2): e000818.

156. Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. *Gut* 2021; 70: 148–156.

157. French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. *Clin Cancer Res* 2008; 14: 3408–3415.

158. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. *Clin Cancer Res* 2012; 18: 890–900.

159. Oh CR, Kim JE, Kang J, et al. Prognostic value of the microsatellite instability status in patients with stage II/III rectal cancer following upfront surgery. *Clin Colorectal Cancer* 2018; 17: e679–e685.

160. Jin Z, Sahnuzea CT, Johnson B, et al. Outcome of mismatch repair-deficient metastatic colorectal cancer: The Mayo Clinic Experience. *Oncologist* 2018; 23: 1083–1091.

161. Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). *Ann Oncol* 2014; 25: 1032–1038.

162. Coupez D, Hulo P, Toucheuf Y, et al. Pembrolizumab for the treatment of colorectal cancer. *Expert Opin Biol Ther* 2020; 20: 219–226.

163. van den Heerik ASVM, Horeweg N, de Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. *Int J Gynecol Cancer* 2021; 31: 594–604.

164. Rouset-Rouviere S, Rochignieux P, Chrétien AS, et al. Endometrial carcinoma: immune microenvironment and emerging treatments in immuno-oncology. *Biomedicines* 2021; 9: 632.

165. Ta RM, Hecht JL and Lin DI. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. *Gynecol Oncol* 2018; 151: 401–406.